相似文献
1
The EP3 Receptor/G Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease.
AAPS J. 2017 Sep;19(5):1276-1283. doi: 10.1208/s12248-017-0097-1. Epub 2017 Jun 5.
2
Pharmacological blockade of the EP3 prostaglandin E receptor in the setting of type 2 diabetes enhances β-cell proliferation and identity and relieves oxidative damage.
Mol Metab. 2021 Dec;54:101347. doi: 10.1016/j.molmet.2021.101347. Epub 2021 Oct 6.
3
Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion.
Diabetes. 2013 Jun;62(6):1904-12. doi: 10.2337/db12-0769. Epub 2013 Jan 24.
4
Opposing effects of prostaglandin E receptors EP3 and EP4 on mouse and human β-cell survival and proliferation.
Mol Metab. 2017 Apr 5;6(6):548-559. doi: 10.1016/j.molmet.2017.04.002. eCollection 2017 Jun.
5
Rat prostaglandin EP3 receptor is highly promiscuous and is the sole prostanoid receptor family member that regulates INS-1 (832/3) cell glucose-stimulated insulin secretion.
Pharmacol Res Perspect. 2021 Apr;9(2):e00736. doi: 10.1002/prp2.736.
6
Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.
Exp Biol Med (Maywood). 2018 Mar;243(6):586-591. doi: 10.1177/1535370218761662. Epub 2018 Mar 4.
7
Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance.
FASEB J. 2016 Jun;30(6):2282-97. doi: 10.1096/fj.201500127. Epub 2016 Mar 1.
8
PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Platelets. 2012;23(5):344-51. doi: 10.3109/09537104.2011.625575. Epub 2012 Mar 21.
9
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease.
Ann Neurol. 2012 Nov;72(5):788-98. doi: 10.1002/ana.23677. Epub 2012 Aug 22.
10
The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice.
Endocrinology. 2016 Jan;157(1):220-32. doi: 10.1210/en.2015-1693. Epub 2015 Oct 20.
引用本文的文献
1
Discovery and Functional Validation of EP3 Receptor Ligands with Therapeutic Potential in Cardiovascular Disease.
Int J Mol Sci. 2025 May 19;26(10):4879. doi: 10.3390/ijms26104879.
2
The prostaglandin E EP3 receptor has disparate effects on islet insulin secretion and content in β-cells in a high-fat diet-induced mouse model of obesity.
Am J Physiol Endocrinol Metab. 2024 May 1;326(5):E567-E576. doi: 10.1152/ajpendo.00061.2023. Epub 2024 Mar 13.
3
Noncanonical Regulation of cAMP-Dependent Insulin Secretion and Its Implications in Type 2 Diabetes.
Compr Physiol. 2023 Jun 26;13(3):5023-5049. doi: 10.1002/cphy.c220031.
4
Plasma Prostaglandin E Metabolite Levels Predict Type 2 Diabetes Status and One-Year Therapeutic Response Independent of Clinical Markers of Inflammation.
Metabolites. 2022 Dec 8;12(12):1234. doi: 10.3390/metabo12121234.
5
Human Islet Expression Levels of Prostaglandin E Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity.
ACS Pharmacol Transl Sci. 2021 Jun 16;4(4):1338-1348. doi: 10.1021/acsptsci.1c00045. eCollection 2021 Aug 13.
6
Prostaglandin EP3 receptor signaling is required to prevent insulin hypersecretion and metabolic dysfunction in a non-obese mouse model of insulin resistance.
Am J Physiol Endocrinol Metab. 2021 Oct 1;321(4):E479-E489. doi: 10.1152/ajpendo.00051.2021. Epub 2021 Jul 6.
7
Effect of Prostanoids on Human Platelet Function: An Overview.
Int J Mol Sci. 2020 Nov 27;21(23):9020. doi: 10.3390/ijms21239020.
8
Agonist-independent Gα activity negatively regulates beta-cell compensation in a diet-induced obesity model of type 2 diabetes.
J Biol Chem. 2021 Jan-Jun;296:100056. doi: 10.1074/jbc.RA120.015585. Epub 2020 Nov 24.
9
Correlative Study on Impaired Prostaglandin E2 Regulation in Epicardial Adipose Tissue and its Role in Maladaptive Cardiac Remodeling via EPAC2 and ST2 Signaling in Overweight Cardiovascular Disease Subjects.
Int J Mol Sci. 2020 Jan 14;21(2):520. doi: 10.3390/ijms21020520.
本文引用的文献
1
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.
Cardiovasc Diabetol. 2017 Feb 2;16(1):18. doi: 10.1186/s12933-017-0499-5.
2
Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes.
Trends Mol Med. 2017 Feb;23(2):181-194. doi: 10.1016/j.molmed.2016.12.005. Epub 2017 Jan 21.
3
Communication between natural killer T cells and adipocytes in obesity.
Adipocyte. 2016 Sep 29;5(4):389-393. doi: 10.1080/21623945.2016.1241913. eCollection 2016 Oct-Dec.
4
TLR4-dependant pro-inflammatory effects of HMGB1 on human adipocyte.
Adipocyte. 2016 Oct 10;5(4):384-388. doi: 10.1080/21623945.2016.1245818. eCollection 2016 Oct-Dec.
5
Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation.
J Cancer. 2016 Nov 26;7(15):2346-2359. doi: 10.7150/jca.16884. eCollection 2016.
6
A comprehensive map of molecular drug targets.
Nat Rev Drug Discov. 2017 Jan;16(1):19-34. doi: 10.1038/nrd.2016.230. Epub 2016 Dec 2.
7
Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance.
Mol Cell Biochem. 2017 Feb;426(1-2):27-45. doi: 10.1007/s11010-016-2878-8. Epub 2016 Nov 21.
8
Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Diabetes Care. 2017 Jan;40(1):117-124. doi: 10.2337/dc16-1580. Epub 2016 Oct 19.
9
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
10
The role of adipokines in chronic inflammation.
Immunotargets Ther. 2016 May 23;5:47-56. doi: 10.2147/ITT.S73223. eCollection 2016.
Zotero 插件